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Abstract
The unique feature ofmitochondrial complex I is the so-called A/D transition (active–deactive transition). The
A-form catalyses rapid oxidation of NADH by ubiquinone (k ∼104 min− 1) and spontaneously converts into the
D-form if the enzyme is idle at physiological temperatures. Such deactivation occurs in vitro in the absence
of substrates or in vivo during ischaemia, when the ubiquinone pool is reduced. The D-form can undergo
reactivation given both NADH and ubiquinone availability during slow (k ∼1–10min− 1) catalytic turnover(s).
We examined known conformational differences between the two forms and suggested a mechanism
exerting A/D transition of the enzyme. In addition, we discuss the physiological role of maintaining the
enzyme in the D-form during the ischaemic period. Accumulation of the D-form of the enzyme would
prevent reverse electron transfer from ubiquinol to FMN which could lead to superoxide anion generation.
Deactivation would also decrease the initial burst of respiration after oxygen reintroduction. Therefore
the A/D transition could be an intrinsic protective mechanism for lessening oxidative damage during the
early phase of reoxygenation. Exposure of Cys39 of mitochondrially encoded subunit ND3 makes the D-
form susceptible for modiﬁcation by reactive oxygen species and nitric oxide metabolites which arrests the
reactivation of the D-form and inhibits the enzyme. The nature of thiol modiﬁcation deﬁnes deactivation
reversibility, the reactivation timescale, the status of mitochondrial bioenergetics and therefore the degree
of recovery of the ischaemic tissues after reoxygenation.
Introduction
Production of energy in most aerobic cells is provided
by the combined action of the mitochondrial respiratory
chain and ATP synthase. Reducing equivalents from pyridine
nucleotides (NADH) generated in several catabolic pathways
are routed into the energy-converting respiratory chain via
so-called complex I or NADH:ubiquinone oxidoreductase.
This enzyme catalyses the oxidation of matrix NADH by
membrane ubiquinone and is the major entry point for
electrons into the respiratory chain. Unlike the 14-subunit
prokaryotic enzyme, mitochondrial complex I contains
approximately 30 additional so-called accessory subunits,
many with still unknown functions. All known redox
centres of this enzyme (FMN and FeS clusters) are located
within core subunits in the hydrophilic domain of the
enzyme, whereas proton translocation is carried out by
several Na+ /H+ antiporter-like subunits. Recent progress
in structural studies [1,2] has led to significant improvements
in the understanding of the coupling mechanism of this
enzyme [1,3], whereas many aspects of regulation are still
not completely understood. Dysfunction of complex I was
found to correlate with a number of clinical conditions
Key words: active–deactive transition (A/D transition), mitochondrial complex I, hypoxia,
ischaemia, thiol modiﬁcation, thiol nitrosation.
Abbreviations used: A/D transition, active–deactive transition; ROS, reactive oxygen species;
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such as Leber’s optic neuropathy, neuromuscular disorders,
Parkinson’s disease and the process of aging.
The unique property of the mitochondrial enzyme
from several vertebrate species is the so-called A/D
transition (active–deactive transition) [4,5]. In mammals,
the catalytically competent A-form of the enzyme operates
at physiological temperatures (>30◦C) when substrates are
available (k ∼104 min− 1). When the enzyme is idle, it
spontaneously converts into the dormant D-form. This form
can potentially undergo reactivation given the availability
of both substrates (NADH and ubiquinone). As a result
of slow (k ∼1–10 min− 1) catalytic turnover(s), the D-form
is converted back into the A-form and this process can
be significantly slowed by the presence of fatty acids (in
conjunction with Ca2 + ) and by alkaline pH [6,7].
Structural differences between A- and
D-forms of complex I
In spite of observed heterogeneity of mitochondrial complex
I in the pioneering work of Estabrook and co-workers [8],
very little is known about structural differences between the
A- and the D-form of the enzyme. It was first established
that upon thermal treatment (37◦C), the NADH oxidase
activity of the enzyme in SMP (submitochondrial particles)
could be inhibited by thiol-group-specific reagents and this
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sensitivity was eliminated by incubation with substrates [9].
Later, the existence of the A- and the D-form was postulated
for the enzyme in SMP and preparation of isolated complex
I [10]. It is important to note that no differences in the
polypeptide composition between the A- and the D-form of
enzyme was later found [11,12], indicating that the sensitivity
of the D-form is associated with the exposure of the
cysteine-containing domain of known complex I subunit(s).
To identify this subunit, Gavrikova and Vinogradov [11]
used N-fluorescein maleimide to label the cysteine residue(s)
that becomes exposed after deactivation of the enzyme in
SMP. The conformation-specific labelling revealed a strong
increase in fluorescence intensity in the region of 15 kDa
only in the D-form. Using membrane-permeant [NEM
(N-methylmaleimide)] and -impermeant [5,5′-dithiobis-(2-
nitrobenzoic acid)] reagents, it was found that the critical
cysteine residue accessible for chemical modification in the
D-form was located at the matrix side of the enzyme [13].
This thiol group has subsequently been identified as Cys39 of
the mitochondrially encoded subunit ND3 (Nqo7/NuoA)
and is accessible only in the D-form of complex I [12].
This residue is indeed oriented towards the matrix and
located in the hydrophilic loop connecting the second and
third transmembrane segments of the ND3 subunit [12]
(Figure 1A). Moreover, several pathogenic mutations close
to Cys39 were found, indicating the importance of this region
for complex I function [14–16].
Cys39 of ND3 is highly conserved among eukaryotes
(conserved to 99% over 108 sequences) (Figure 1B). The
corresponding prokaryotic Nqo7 subunit from Paracoccus
denitrificans and NqoA from Rhodobacter capsulatus
contains a homologue of the cysteine residue, whereas in
Escherichia coli and Thermus thermophilus, it is replaced by
serine. Composed of more than 40 subunits, the eukaryotic
enzyme in vertebrates, such as cow [10], rat [17], mouse [18],
chicken, frog and carp [5] displays the A/D transition as
well as the 37–39-subunit complex I from fungi [5]. Despite
the occurrence of the cysteine residue, the bacterial complex
I from P. denitrificans and enzyme from non-vertebrate
organisms, such as earthworm (Lumbricus terrestris), lobster
(Homarus americanus) and cricket (Acheta domesticus), does
not manifest patterns of the A/D transition [5]. Therefore the
presence of this unique cysteine residue in the ND3 sequence
does not correlate with the apparent ability of complex I to
undergo the A/D transition (Figure 1B).
The fact that the A/D transition has a high activation
energy [10] favours the idea of significant conformational
changes upon deactivation. It has been reported that at least
one other subunit might be involved in the A/D transition
process. Indeed, the disruption of the 29.9 kDa subunit in
Neurospora crassa (B13 in the bovine enzyme) led to a
lower rate of thermal deactivation of complex I [19]. This
hydrophilic subunit is well conserved from mammals to
plants and fungi, but the function of B13 remains unknown.
Recently, using a 6.8 A˚ (1 A˚ = 0.1 nm) het-
erobifunctional cross-linker, SPDP (succinimidyl 3-(2-
pyridyldithio)propionate], we demonstrated that ND3 was
closely located to the 39 kDa subunit (NDUFA9) in the D-
form of complex I in SMP [20]. These two subunits formed
a cross-linked product only in the D-form of the enzyme,
and not in the A-form. This finding indicates that, upon
deactivation, the position of Cys39 changes and it can be cross-
linked to one of the lysine residues of the 39 kDa subunit
in the vicinity. The latter is one of the accessory subunits
from the family of heterogeneous short-chain dehydro-
genase/reductases and contains a non-covalently bound
NADPH molecule [21,22]. Therefore the 39 kDa subunit
can be positioned at the interface between the membrane
part and the hydrophilic part of complex I very close to the
region of enzyme which is involved into A/D transition. This
corresponds to the location of that subunit suggested for the
isolated bovine enzyme [23,24]. Deletion of this subunit in
yeast significantly destabilizes the complex I structure [21].
A close physical proximity of ND3 with 49 kDa (Nqo4)
and PSST (Nqo6) subunits in P. denitrificans has been proved
biochemically [25] and confirmed after resolution of the
structure of the entire complex I from T. thermophilus [1].
Subunits PSST and 49 kDa are involved in the formation
of terminal FeS cluster N2 and, along with ND3 and
ND1, form a sealed quinone-binding cavity away from the
membrane bilayer. The first transmembrane segment of ND3
is located in between two transmembrane segments of ND1
(Nqo8/NuoH) (Figure 1A). In the T. thermophilus enzyme,
the hydrophilic loop containing Ser46 of Nqo7 (Cys39 in
ND3) is part of the seal for the quinone-binding cavity
[1]. Thus the hydrophilic interhelical loop of ND3 is a
part of a crucial region where the energy of the redox
reaction is transduced into conformationally driven proton
translocation across the membrane part of the enzyme,
probably via antiporter-like subunits [1]. The relocation
of the hydrophilic part of ND3 upon deactivation of the
mammalian enzyme could lead to a change in the quinone
chamber, affecting interaction of the quinone headgroup
with its binding site [1]. Partial opening of the well-sealed
electron-transport pathway within the enzyme may explain
the increased rate of ROS (reactive oxygen species) formation
by the D-form of the enzyme [18,26].
The exact molecular mechanism exerting the A/D trans-
ition is unknown. One possibility is that a conformational
change resulting in exposure of the critical Cys39 of ND3
involves other accessory subunits of the eukaryotic enzyme in
the vicinity, e.g. 39 kDa subunit or B13 [19,20]. Alternatively,
movement of the loop itself exerts the A/D conformational
changes of complex I. In the bovine ND3 subunit, this
loop is composed of 27 amino acids. Together with two
proline residues that are located at the interface between the
transmembrane helices, two to three other proline residues
are found to be well-conserved in vertebrates (Figure 1B).
Peptidylprolyl cis–trans isomerization has emerged as a
conformational switch regulating processes such as ion
channel gating [27] and protein domain movement ([28],
and see [29] for review). It would be tempting to speculate
that local bond rearrangement at the ‘hinge’ point could
propagate through the protein backbone and would result
C©The Authors Journal compilation C©2013 Biochemical Society
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Figure 1 Location of the hydrophilic loop of Nqo7 subunit (T. thermophilus [1]), shown in blue, which is homologous with
mitochondrially encoded subunit ND3
(A) The Ser36 homologue of Cys39 of ND3 is shown in purple and proline residues are shown in cyan. Note that this loop is
located in close proximity to the quinone-binding site and terminal cluster N2. (B) Partial alignment of the homologues of
ND3. Hydrophilic loop containing the critical Cys39 is shown in a box.
in opening/closing of the flap formed by the loop. The
isomerization is a slow reaction with an activation energy
of approximately 100 kJ/mol occurring within the minute
timescale [29] which corresponds to known parameters of
A/D transition [10]. Introduction of negative charge as a
result of deprotonation of the functional group close to the
critical isomerizing proline residue significantly decelerates
rotation of the imide bond and could explain the decrease
in activation rate of complex I at higher pH [7]. Therefore
the A/D transition would be regarded as an equilibrium
between cis and trans isoforms of critical proline(s) in the
hydrophilic loop of ND3. The energetically more stable
trans prolyl bond could be adopted in the D-form, whereas
isomerization results in closing of the flap and sealing of the
quinone-binding cavity. On the other hand, conformational
change induced by trans/cis proline isomerization in the
hydrophilic loop affecting the position of the membrane helix
or helices of ND3 cannot be excluded. The presence in the
mitochondrial matrix of specific peptidylprolyl isomerases
such as cyclophilin D, suggested to be associated with
complex I [30], could be an important factor modulating the
kinetics of the A/D transition in situ.
C©The Authors Journal compilation C©2013 Biochemical Society
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Figure 2 Time-course of de-activation of mitochondrial complex I
in rat heart (A) and brain (B) tissue after cardiac arrest
Percentage of the D-form in samples was determined as described in
[18].
Physiological effect of the A/D transition
The physiological role of the A/D transition is still under
discussion. Under conditions when the respiratory rate is
decreased, e.g. at limited O2 concentration (or metabolic
hypoxia [31]), the respiratory chain is reduced due to the
slowing down of cytochrome c oxidase. As a result, the
turnover of complex I becomes limited because of the lack of
the electron acceptor ubiquinone. In this situation, the steady-
state equilibrium in the A↔D reaction would be shifted to
the right, and complex I in highly metabolizing tissues such
as heart or brain would be readily converted into the D-form
in a minute timescale [18,32] (Figure 2). In the Langendorf rat
heart model and mouse infarction model, reperfusion results
in the return of complex I A/D equilibrium to its initial level,
indicating that reintroduction of oxygen causes reactivation
of the D-form of the enzyme [18,32].
Therefore the A/D transition is a natural adaptive
mechanism mediating mitochondrial response to hypoxia. In
this section, we discuss several views on the role of the A/D
transition of complex I.
(i) Initially, deactivation was considered as special mech-
anism preventing proton leakage to the mitochondrial matrix
from the intermembrane space through the idle enzyme and
decrease in protonmotive force [33]. However, later, it was
found that the D-form of the enzyme in submitochondrial
particles is still able to translocate protons during NADH
oxidation by hydrophilic short-chain quinone analogues [34].
(ii) Recently, potential Na+ /H+ antiporter activity was
elegantly demonstrated for the D-form of bovine complex I
in a reconstituted system and SMP [35]. There is a significant
rise in intracellular Na+ concentration in cytoplasm upon
oxygen deprivation [36]. It was suggested that the Na+ /H+
exchange catalysed by the D-form accumulated during the
ischaemic period and can contribute to the protection of
mitochondrial ion balance [35]. However, on the basis of the
redox-dependent proton-pumping mechanism proposed for
complex I [1,3], the Na+ movement through the enzyme
antiporter-like subunits is likely to operate via a different
route for which the details are still not known. Moreover,
it was demonstrated that increased Na+ /H+ exchange
in ischaemia leads to mitochondrial damage [37] and
inhibition of antiporter activity protects mitochondria during
reperfusion or attenuates oxidative stress in cardiomyocytes
[38,39]. Decreased rates of overall Na+ /Ca2 + exchange
shown in mitochondria from ischaemic heart samples also
suggest a decrease and not an increase in Na+ /H+ exchange
across the inner membrane when oxygen is lacking [40]. The
role of mitochondria in regulating Na+ concentration in
cytosol in ischaemia is not completely understood at present
and more research is needed to elucidate the involvement of
complex I in Na+ balance during ischaemia.
(iii) In ischaemia/reperfusion models, diminution of
respiratory activity during reoxygenation would protect
mitochondria from irreversible damage [41,42]. Therefore it
is possible that slow activation of the D-form upon tissue
reoxygenation may function as a protective valve and reduce
the burst of respiration and consequent ROS production
at the level of complex I or downstream sites. In addition,
deactivation of the enzyme could prevent superoxide anion
generation from the reduced flavin since the D-form does not
catalyse reverse electron transfer from ubiquinol to FMN [7].
(iv) As shown previously, in tissues ex vivo [18,32] (but
not in cells [43]), a significant fraction of the enzyme (5–
15%) was found to be in the D-form at the physiological
O2 concentration (Figure 2). Therefore, in situ, part of the
energy released during steady-state NADH oxidation is used
to maintain the catalytically competent A-state of the enzyme
as suggested previously [4]. Maintenance of the fraction of
complex I in the D-form would allow fast responses to
changes in conditions such as a reductive pressure, ATP
demand and oxygen availability by analogy with the well-
known phenomenon of excess capacity of cytochrome c
oxidase [44–46]. Therefore the A/D transition could be one of
the mechanisms for fine-tuning enzyme activity in different
tissues [5,18,47,48]. The time course of complex I deactivation
after cardiac arrest reveals a much higher A/D transition rate
in brain compared with heart tissue (Figure 2) and might
explain the greater vulnerability of complex brain functions
to oxygen deprivation.
Exposure of Cys39 in the D-form [11,12,49] can be
very important in various pathological scenarios. Sensitivity
C©The Authors Journal compilation C©2013 Biochemical Society
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of the D-form of complex I to covalent modification
led to the proposal of possible regulation of enzyme
activity via thiol-reactive natural effectors such as the GSH–
GSSG couple [4]. Although no sensitivity of the D-form
of the enzyme to reduced or oxidized glutathione was
found in in vitro experiments [13,48], only the D-form
of complex I was susceptible to inhibition by nitric oxide
metabolites [48,49] and ROS [18]. Oxidation of Cys39
of ND3 in the D-form by H2O2 results in irreversible
inhibition of the enzyme [18]. It was found recently
that S-nitrosation of Cys39 of ND3 by mitochondrially
targeted nitrosothiol MitoSNO protects cardiac tissue during
ischaemia/reperfusion in mice in vivo [49]. Modification of
cysteine thiols in situ depends on particular biochemical
conditions that an attacking group could encounter: redox
environment and hydrophobicity surrounding the target
thiol, pH, ion composition, nitric oxide/O2 ratio and activity
of enzymes mediating action of ROS and nitric oxide
metabolites [50]. These conditions could vary significantly
during oxygen deprivation in tissues. The magnitude of
such modification of complex I is not clear at present.
Prolonged exposure of the D-form of the enzyme to low
steady-state levels of endogenous thiol-reactive molecules
such as H2O2, S-nitrosoglutathione or peroxynitrite would
lead to modification of some fraction of the enzyme. S-
nitrosation of the ND3 subunit is reversible, probably via
reduction by glutathione and thioredoxin systems [49], but
nitration or oxidation is irreversible at the timescale of the
ischaemia/reperfusion process (tens of minutes). Depending
on the nature of modification, the fraction of the modified
enzyme would gradually increase over time. Taking into
account the high degree of flux control of complex I over
oxidative phosphorylation [51,52], elimination of even a
small fraction of the enzyme may lead to a significant
decrease in ATP production by mitochondria, although no
apparent effect is observed on activity of the respiratory
chain [53]. Such modification of the D-form would result
in the emergence of a mitochondrial population with altered
ATP-generating capacity/ionic balance. Depending on the
timeframe of the process and the size of such a population,
recovery of the ischaemic tissues after reperfusion could be
significantly affected.
Conclusion
At a structural level, the mechanism of A/D conformational
changes of eukaryotic complex I remains unclear, as its driving
force and the involvement of accessory subunits are still
unknown. It is very likely that the 39 kDa subunit is also
involved in conformational changes upon deactivation.
Our observations suggest that accumulation of the D-
form of the enzyme takes place in highly metabolizing tissues
during ischaemia. A/D transition can be considered a natural
intrinsic mechanism providing diminution of activity of the
respiratory chain during the initial phase of reoxygenation
and would protect mitochondria from irreversible damage.
Cys39 of the ND3 subunit, exposed in the D-form, is
susceptible to covalent modification by ROS and nitric
oxide metabolites. It is possible that the accumulated D-
form can react with natural effectors in mitochondria or
with pharmacological agents during periods of hypoxia
or reoxygenation, modulating the process of reactivation of
the enzyme and outcome of ischaemia/reperfusion.
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